Business Description
Vaidya Sane Ayurved Laboratories Ltd
ISIN : INE0JR301013
Total Employee Number:
413Compare
Compare
Traded in other countries / regions
MADHAVBAUG.India IPO Date
2022-02-23Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.92 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.15 | |||||
Interest Coverage | 10.93 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8.57 | |||||
Beneish M-Score | -1.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.5 | |||||
3-Year EBITDA Growth Rate | 22 | |||||
3-Year EPS without NRI Growth Rate | 20.5 | |||||
3-Year FCF Growth Rate | 30.5 | |||||
3-Year Book Growth Rate | 26.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.94 | |||||
9-Day RSI | 72.76 | |||||
14-Day RSI | 63.52 | |||||
3-1 Month Momentum % | -6.37 | |||||
6-1 Month Momentum % | -28.98 | |||||
12-1 Month Momentum % | -2.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.99 | |||||
Quick Ratio | 3.66 | |||||
Cash Ratio | 2.08 | |||||
Days Inventory | 69.39 | |||||
Days Sales Outstanding | 29.14 | |||||
Days Payable | 120.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.1 | |||||
Shareholder Yield % | -8.31 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.29 | |||||
Operating Margin % | 8.69 | |||||
Net Margin % | 8.41 | |||||
EBITDA Margin % | 16.64 | |||||
FCF Margin % | -2.31 | |||||
OCF Margin % | 5.06 | |||||
ROE % | 12.38 | |||||
ROA % | 10.24 | |||||
ROIC % | 12.36 | |||||
3-Year ROIIC % | 6.96 | |||||
ROC (Joel Greenblatt) % | 47.62 | |||||
ROCE % | 15.21 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 25.48 | |||||
PE Ratio without NRI | 25.48 | |||||
Price-to-Owner-Earnings | 118.49 | |||||
PEG Ratio | 1.2 | |||||
PS Ratio | 2.16 | |||||
PB Ratio | 2.8 | |||||
Price-to-Tangible-Book | 3.27 | |||||
Price-to-Operating-Cash-Flow | 39.97 | |||||
EV-to-EBIT | 16.73 | |||||
EV-to-EBITDA | 10.96 | |||||
EV-to-Revenue | 1.82 | |||||
EV-to-FCF | -70.07 | |||||
Price-to-GF-Value | 0.9 | |||||
Price-to-Projected-FCF | 5.11 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.2 | |||||
Price-to-Graham-Number | 1.92 | |||||
| Price-to-Net-Current-Asset-Value | 8.98 | |||||
| Price-to-Net-Cash | 40.81 | |||||
Earnings Yield (Greenblatt) % | 5.97 | |||||
FCF Yield % | -1.15 | |||||
Forward Rate of Return (Yacktman) % | 16.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vaidya Sane Ayurved Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,069.064 | ||
| EPS (TTM) (₹) | 8.04 | ||
| Beta | 1.2857 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.03 | ||
| Volatility % | 83.91 | ||
| 14-Day RSI | 63.52 | ||
| 14-Day ATR (₹) | 8.678838 | ||
| 20-Day SMA (₹) | 184.0225 | ||
| 12-1 Month Momentum % | -2.92 | ||
| 52-Week Range (₹) | 150 - 335 | ||
| Shares Outstanding (Mil) | 10.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vaidya Sane Ayurved Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vaidya Sane Ayurved Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vaidya Sane Ayurved Laboratories Ltd Frequently Asked Questions
What is Vaidya Sane Ayurved Laboratories Ltd(NSE:MADHAVBAUG)'s stock price today?
The current price of NSE:MADHAVBAUG is ₹204.85. The 52 week high of NSE:MADHAVBAUG is ₹335.00 and 52 week low is ₹150.00.
When is next earnings date of Vaidya Sane Ayurved Laboratories Ltd(NSE:MADHAVBAUG)?
The next earnings date of Vaidya Sane Ayurved Laboratories Ltd(NSE:MADHAVBAUG) is .
Does Vaidya Sane Ayurved Laboratories Ltd(NSE:MADHAVBAUG) pay dividends? If so, how much?
Vaidya Sane Ayurved Laboratories Ltd(NSE:MADHAVBAUG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Vaidya Sane Ayurved Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers